Pharmacy

Your Article Summary

See Latest Articles

Fyi from human genome sciences: glaxosmithkline study shows gsk's novel diabetes treatment syncria (albiglutide) improves glucose control, reduces weight
Human Genome Sciences, 06/09/09

Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit royalties on worldwide sales if Syncria is commercialized.

Today in Basic Science...keeping you current

Receive free subspecialty "5-minute updates" via email

Stable expression, activity and inducibility of cytochromes p450 in differentiated heparg cells
Drug Metabolism and Disposition, 12/18/09

The regulation of neuronal gene expression by alcohol
Pharmacology & Therapeutics, 12/18/09

The pleiotropy of dioxin toxicity — Xenobiotic misappropriation of the aryl hydrocarbon receptor's alternative physiological roles
Pharmacology & Therapeutics, 12/17/09

 See all of Basic Science

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09

Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09

Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09

 See all of Major Studies